A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.

  • Burgell, Rebecca (Primary Chief Investigator (PCI))
  • McKenzie, Jo (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date26/03/2031/12/25

Keywords

  • Gastroenterology
  • Diabetic Gastroparesis
  • Clinical trial